Makary Exit Leaves FDA Future and Abortion Pill Rules in Flux
Cover image from salon.com, which was analyzed for this article
Outgoing FDA head Marty Makary's departure creates uncertainty, with left warning of threats to nationwide abortion access via mail-order pills. Pro-life advocates await Trump admin action to restrict drugs. Bipartisan scrutiny intensifies on agency direction.
PoliticalOS
Wednesday, May 13, 2026 — Politics
Makary's exit creates leadership uncertainty at the FDA but does not automatically alter mifepristone rules, which remain subject to ongoing court review and any future commissioner's actions. Readers should track the next nominee's confirmation hearings for concrete signals on drug-safety reviews rather than assuming immediate nationwide policy shifts.
What outlets missed
Most coverage omitted documented FDA actions under Makary such as accelerated biosimilar pathways and revised vaccine frameworks listed on the agency's site. RFK Jr.'s public praise for Makary's work advancing MAHA priorities received little attention outside scattered reports. Details on Diamantas's prior legal work and the precise status of any ongoing mifepristone review remained unverified across outlets, with claims of deliberate delays or imminent bans lacking independent confirmation from FDA records.
Outgoing FDA Commissioner Marty Makary's departure injects fresh uncertainty into an agency already navigating leadership gaps and competing political demands. The move follows months of friction over drug approvals, including mifepristone used in medication abortions, and leaves acting leadership in the hands of Kyle Diamantas, previously head of the FDA's food center. Stakeholders on both sides now watch for whether a permanent successor will accelerate or slow reviews of the drug's distribution rules.
Makary, confirmed in March 2025, oversaw more than 20 regulatory actions during his 13-month tenure, among them steps to speed biosimilar approvals, reduce animal testing requirements, and remove certain safety warnings from menopause hormone therapies. President Trump publicly called him a hard worker respected by colleagues while noting internal difficulties accommodating administration priorities. Diamantas, described by some former HHS officials as possessing regulatory experience suited to a transition, now manages day-to-day operations amid vacancies in the centers for drugs and biologics.
Axios centered agency instability and Senate logistics. Salon highlighted potential loss of abortion-pill access. The Federalist stressed pro-life momentum and called for restored restrictions. All three relied on unverified quotes or timelines that other outlets could not corroborate.
Behind the Coverage
axios.com
Most biased
salon.com
thefederalist.com
Least biased
What each outlet got wrong
axios.com
Framed Makary's tenure as defined by 'organizational upheaval and political jockeying that marked much of his 13-month tenure' and 'political interference have come to characterize an agency once known for predictability and evidence-based decision-making,' using unverified quotes like Sen. Dick Durbin's 'I hope Dr. Makary will inspire others within the Trump administration to grow a spine.'
Our version: The neutral version balances this by listing over 20 specific regulatory achievements under Makary, such as speeding biosimilar approvals and reducing animal testing, while noting Trump's praise as a 'hard worker respected by colleagues' amid internal difficulties.
salon.com
Used the sensational title 'FDA exit could threaten abortion access nationwide' and repeatedly labeled critics as 'anti-abortion activists' or 'strident abortion opponent' like Sen. Josh Hawley, while featuring loaded quotes such as 'chemical abortion pills that kill preborn babies.'
Our version: The neutral version avoids alarmism by presenting both stakeholders' views equally—abortion opponents pressing for in-person requirements and safety reviews versus medical groups affirming the drug's safety profile—without pejorative labels.
thefederalist.com
Presented contested data as undisputed fact with 'linked to an 11 percent maternal injury rate' and exclusively quoted pro-life figures like Sen. Josh Hawley calling Makary 'uniquely destructive to the prolife movement' who 'slow walked a vitally necessary review.'
Our version: The neutral version contextualizes mifepristone debates by noting critics' arguments on emergency-room data and oversight alongside medical groups' safety claims, without endorsing disputed rates or one-sided advocacy.
Facts outlets left out
Makary oversaw more than 20 regulatory actions, including steps to speed biosimilar approvals, reduce animal testing requirements, and remove safety warnings from menopause hormone therapies.
Omitted by: axios.com, thefederalist.com
President Trump publicly praised Makary as a 'hard worker, who was respected by all' on Truth Social.
Omitted by: salon.com, thefederalist.com
Kyle Diamantas is described by former HHS officials as having regulatory experience suited to a transition, now managing amid vacancies.
Omitted by: salon.com, thefederalist.com
Medical groups maintain mifepristone's overall safety profile supports current rules.
Omitted by: thefederalist.com
Framing tricks we caught
Declarative framing of controversy
“Axios: 'organizational upheaval and political jockeying that marked much of his 13-month tenure' and 'surprise policy moves, organizational upheaval and political jockeying have come to characterize an agency.'”
Neutral alternative: Neutral rewrite notes 'friction over drug approvals' and 'competing political demands' without declaring the entire tenure as upheaval.
Loaded headline
“Salon: 'FDA exit could threaten abortion access nationwide.'”
Neutral alternative: Neutral uses 'Outgoing FDA Commissioner Marty Makary's departure injects fresh uncertainty,' focusing on uncertainty without speculating threats.
One-sided sourcing
“TheFederalist.com exclusively quotes pro-life advocates like Marjorie Dannenfelser: 'We look forward to a new FDA Commissioner who will put an end to the mail-order abortion drug regime.'”
Neutral alternative: Neutral includes views from 'abortion opponents, including Sen. Josh Hawley' and 'medical groups' for balance on mifepristone rules.